---
figid: PMC11611323__ijmm-55-02-05461-g02
figtitle: Action of AdA in NAFLD
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11611323
filename: ijmm-55-02-05461-g02.jpg
figlink: /pmc/articles/PMC11611323/figure/F3/
number: F3
caption: Mechanism of action of AdA in NAFLD. Enhancing endogenous synthesis and decreasing
  catabolism of AdA in hepatic peroxisomes notably increases levels of AdA-free and
  AdA-containing phospholipids in the liver and plasma. This can lower hepatic glucose
  levels and decrease peroxisomal oxidation, contributing to liver steatosis. Exogenous
  AdA treatment elevates cellular ROS, decreases the expression of the antioxidant
  enzyme Gpx1, causes oxidative stress damage and impairs cell viability. AdA also
  raises mRNA levels of chemokines IL-8, MIP1β and MCP1, which promote inflammation
  and fibrosis. In vitro, exogenous AdA stimulation of TCR DNT cells induces apoptosis
  by downregulating the PI3K/AKT signalling pathway and its downstream molecule, c-Myc.
  This reduces GZMB secretion, increases pro-inflammatory CD4+ and CD8+ T cells and
  decreases anti-inflammatory CD8+ Treg levels, thereby diminishing the immunosuppressive
  function of TCRαβ DNT cells and advancing NAFLD progression. AdA, adrenic acid;
  NAFLD, non-alcoholic fatty liver disease; ROS, reactive oxygen species; Gpx, glutathione
  peroxidase; MIP, macrophage inflammatory protein; MCP, chemoattractant protein;
  TCR, T cell receptor; DNT, double-negative T; GZMB, granzyme B; Treg, regulatory
  T cell
papertitle: 'Adrenic acid: A promising biomarker and therapeutic target (Review)'
reftext: Ze Wang, et al. Int J Mol Med. 2025 Feb;55(2).
year: '2025'
doi: 10.3892/ijmm.2024.5461
journal_title: International Journal of Molecular Medicine
journal_nlm_ta: Int J Mol Med
publisher_name: Spandidos Publications
keywords: adrenic acid | metabolic disease | atherosclerosis | neurological disease
  | mechanism of action | regulatory approach | clinical application
automl_pathway: 0.9549949
figid_alias: PMC11611323__F3
figtype: Figure
redirect_from: /figures/PMC11611323__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11611323__ijmm-55-02-05461-g02.html
  '@type': Dataset
  description: Mechanism of action of AdA in NAFLD. Enhancing endogenous synthesis
    and decreasing catabolism of AdA in hepatic peroxisomes notably increases levels
    of AdA-free and AdA-containing phospholipids in the liver and plasma. This can
    lower hepatic glucose levels and decrease peroxisomal oxidation, contributing
    to liver steatosis. Exogenous AdA treatment elevates cellular ROS, decreases the
    expression of the antioxidant enzyme Gpx1, causes oxidative stress damage and
    impairs cell viability. AdA also raises mRNA levels of chemokines IL-8, MIP1β
    and MCP1, which promote inflammation and fibrosis. In vitro, exogenous AdA stimulation
    of TCR DNT cells induces apoptosis by downregulating the PI3K/AKT signalling pathway
    and its downstream molecule, c-Myc. This reduces GZMB secretion, increases pro-inflammatory
    CD4+ and CD8+ T cells and decreases anti-inflammatory CD8+ Treg levels, thereby
    diminishing the immunosuppressive function of TCRαβ DNT cells and advancing NAFLD
    progression. AdA, adrenic acid; NAFLD, non-alcoholic fatty liver disease; ROS,
    reactive oxygen species; Gpx, glutathione peroxidase; MIP, macrophage inflammatory
    protein; MCP, chemoattractant protein; TCR, T cell receptor; DNT, double-negative
    T; GZMB, granzyme B; Treg, regulatory T cell
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADA
  - ADAD1
  - ADAD2
  - ADAR
  - ADARB1
  - ADARB2
  - ADAT1
  - ADAT2
  - ADAT3
  - CXCL8
  - NT5C
  - CCL2
  - CD36
  - GPX1
  - AKT1
  - AKT2
  - AKT3
  - MYC
  - CD4
  - TNPO1
  - RPTOR
  - MAPKAP1
  - GZMB
  - CD8A
  - CD8B
  - TRA
  - TRAV29DV5
  - TRAJ60
  - TRAC
  - ROS
---
